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As the clinical symptoms of the antiphospholipid syndrome (APS) frequently occur irrespective of the syndrome,
diagnosis predominantly depends on the laboratory assays measuring the level or function of antiphospholipid
antibodies (aPLs). β2-glycoprotein I (β2GPI) is increasingly accepted as the most important target of aPLs. Anti-
β2GPI antibodies constitute a heterogeneous population, but current in vivo and in vitro evidence show that
especially the first domain (DI) of β2GPI contains an important pathogenic epitope. This epitope containing
Glycine40-Arginine43 (G40-R43) has proven to be cryptic and only exposed when β2GPI is in its open con-
formation. A previous study demonstrated a highly variable exposure of the cryptic epitope in commercial anti-
β2GPI assays, with implications on correct patient classification. Unexpectedly, recent unpublished data re-
vealed impaired exposure of the pathogenic epitope in the commercially available anti-DI chemiluminescence
immunoassay (CIA) assay detecting specific antibodies directed to DI.
In this review we summarize the laboratory and clinical performance characteristics of the different anti-DI
assays in published data and conclude with inconsistent results for both the correlation of anti-DI antibodies with
clinical symptoms and the added value of anti-DI antibodies in the classification criteria of APS. Additionally, we
hypothesize on possible explanations for the observed discrepancies. Finally, we highly advise manufacturers to
use normal pooled plasma spiked with the monoclonal anti-DI antibodies to verify correct exposure of the cryptic
epitope.
1. Introduction
APS is a systemic autoimmune disease characterized by thrombotic
complications, either venous, arterial, or small-vessel thrombosis, or
pregnancy-related morbidity. The latter includes fetal death, premature
births attributed to placental insufficiency, eclampsia or severe pre-
eclampsia and spontaneous abortions [1]. Given the high frequency of
these clinical symptoms irrespective of the syndrome, apart from a
clinical characteristic an APS patient needs to fulfil at least one of the
laboratory criteria [2]. Current revised laboratory criteria for APS
classification detect the presence of aPLs through a combination of la-
boratory assays, including one functional coagulation assay lupus an-
ticoagulant (LAC) and two immunological assays measuring im-
munoglobulin (Ig) G and/or IgM anti-cardiolipin antibodies (anti-CL)
and IgG and/or IgM anti-β2GPI antibodies (anti-β2GPI). To avoid false
positive tests due to infections, positive tests should be repeated with an
interval of at least 12 weeks [3]. Of note, the presence of these aPLs has
also been demonstrated to associate with other clinical symptoms that
are not included in the APS criteria, such as epilepsy and migraine
[4,5].
Probably due to the fact that LAC measures a functional effect of the
antibodies, LAC is a better predictor of thrombosis than the quantitative
solid-phase immunoassays. However, currently it is not advised to carry
out LAC tests during treatment with direct oral anticoagulants because
of the risk of false-positive results [6]. The exact pathogenesis of APS is
unknown, but aPLs have been described to activate monocytes, neu-
trophils, dendritic cells and the placental tissue (summarized in [7]).
Despite the fact that many different proteins have been identified as
being involved in the pathogenesis of APS, accumulating evidence from
in vitro experiments as well as animal studies has revealed that β2GPI is
the main target for aPLs [8–10]. Based on this evidence, one would
expect that testing for antibodies with reactivity towards β2GPI has a
https://doi.org/10.1016/j.autrev.2018.06.011
Received 12 June 2018; Accepted 18 June 2018
⁎ Corresponding author at: Synapse BV, Oxfordlaan 70, Maastricht 6229 EV, the Netherlands.
E-mail addresses: d.yin@thrombin.com (D. Yin), b.delaat@thrombin.com (B. de Laat), Katrien.Devreese@uzgent.be (K.M.J. Devreese),
h.kelchtermans@thrombin.com (H. Kelchtermans).
Autoimmunity Reviews 17 (2018) 1210–1218
Available online 11 October 2018
1568-9972/ © 2018 Elsevier B.V. All rights reserved.
T
good correlation with clinical manifestations. Although numerous stu-
dies have demonstrated a significant correlation [11–13], a meta-ana-
lysis performed by Galli et al. failed to show a significant correlation
between single anti-β2GPI positivity with a history of thrombosis or
fetal loss [14]. The lack of correlation with thrombotic complications as
well as pregnancy morbidity was also shown in more recent studies
[15–17].
The reason for this variation may at least in part result from the
availability of numerous commercial and home-made anti-β2GPI assays
and the lack of standardization [18,19]. The available assays differ from
each other in assay design [method/principle: enzyme-linked im-
munosorbent assay (ELISA) versus chemiluminescence immunoassays
(CIA)], the source of β2GPI and coating principles, the calculation of
cut-off values, the reference material and the units used to express
positivity [20,21]. Additionally, various subsets of anti-β2GPI anti-
bodies targeting different domains of the protein have been described
with clear differences in clinical potential [22–25]. β2GPI consists of
five homologous domains (DI-DV) arranged differently in its native
versus open conformation [26]. Importantly, in the native circular or S-
shaped β2GPI the critical DI epitope is not exposed. Upon binding to an
anionic (phospholipid) surface through the positively charged patch on
DV, β2GPI undergoes a conformational change. Consequently, the DI-IV
spreads out resulting in a more open J shape, exposing a cryptic epitope
G40-R43 in DI and allowing anti-DI β2GPI autoantibodies to bind
[27–29]. This subpopulation of aPLs that recognize an epitope on DI of
β2GPI comprising at least G40-R43 proved to be pathogenic [27,30–37]
and displayed a significant correlation with clinical manifestations
[16,38]. The detection of antibodies to DI versus DIV/V has therefore
been suggested to help in the diagnosis of APS [39,40].
As to the in vivo evidence for the pathogenicity of antibodies di-
rected to DI, administration of recombinant human DI was found to
inhibit the induction of thrombosis by polyclonal human IgG from pa-
tients with APS in a mouse model [41,42]. In addition, a recombinant
antibody recognizing DI of β2GPI induced thrombosis and fetal loss in
animal models following priming with lipopolysaccharide (LPS), while
a CH2-deleted version of this antibody prevented the procoagulant and
abortion-inducing effect of aPLs from APS patients [43]. In a proof-of-
concept study, using polyclonal IgG from patients with APS, anti-DI-
rich IgG significantly induced larger thrombi and enhanced the pro-
coagulant activity in vivo compared with anti-DI-poor IgG [44].
Interestingly, a study in our laboratory demonstrated that the ex-
posure of this pathogenic epitope G40-R43 on domain I was highly
variable in commercial full-length anti-β2GPI assays. This reduced ex-
posure of G40-R43 may account for the variable results obtained con-
cerning the clinical correlation of the assays as reduced exposure was
found to result in false negative classification of APS patients [45].
More recently, various assays specifically measuring anti-DI antibodies
have been developed. As these assays are measuring a specific patho-
genic population, one would expect anti-DI assays to highly correlate
with clinical symptoms. Nonetheless, as for the full length anti-β2GPI
assays, no consensus has been reached for the anti-DI antibodies con-
cerning the correlation with clinical symptoms. Whereas some studies
have demonstrated a higher correlation with thrombosis compared to
the full-length assays, other studies failed to show an added value of
anti-DI assays. In this review, we summarize the laboratory and clinical
performance characteristics of the various anti-DI assays and elaborate
on the possible reasons for the observed discrepancies.
2. Available anti-DI assays
So far five major assays have been described in literature to speci-
fically measure antibodies directed to DI of β2GPI (summarized in
Table 1). These five assays differ in the source of DI, the coating and
measuring principle and the interpretation of results. As these factors
may influence the clinical performance of the test, we aim to summarize
and compare the sensitivity and specificity, the odds ratio (OR) of anti- Ta
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DI for clinical manifestations, as well as the added value of anti-DI to
the existing laboratory criteria when measured with the different
available assays in various patient populations (summarized in Tables
2-4).
2.1. In-house developed two-step anti-DI ELISA assay
In 2005, the first anti-DI assay was developed by de Laat et al. [38].
The DI used for coating was produced by a baculovirus expression
system as described before [34]. In this assay, DI is coated on a hy-
drophobic as well as a hydrophilic plate. The arbitrary binding of DI on
a hydrophobic plate will ensure satisfactory exposure of the G40-R43
epitope. On the contrary, on a hydrophilic plate the positive epitope
G40-R43 will be strongly directed downwards making the epitope not
available for binding. The result of the assay is expressed as a ratio
between the optical densities (OD) measured with the hydrophobic
plate versus the hydrophilic plate. A ratio higher than two indicates DI
reactivity of the sample.
This two-step anti-DI ELISA has been utilized in three studies
[16,38,46]. In a single-center study including 198 patients with various
systemic autoimmune diseases both IgG anti-DI and IgG anti-β2GPI
antibodies measured with an in-house ELISA correlated strongly with a
history of thrombosis [OR 18.9, 95% confidence interval (95% CI)
6.8–52.3; OR 6.7, 95% CI 3.4–13.5, respectively] [38]. In contrast,
those with affinity for other domains of β2GPI were not significantly
correlated with thrombosis (OR 1.1, 95% CI 0.4–2.8). Interestingly,
only 58% of IgG anti-β2GPI positive patients were IgG anti-DI positive,
and 93% of the anti-DI positive samples proved to be LAC positive [38].
These findings were confirmed in the consecutive multicenter study
conducted on 442 patients positive for IgG/IgM anti-β2GPI [16]. The
prevalence of IgG anti-DI antibodies positivity was 57% and IgG anti-DI
was significantly associated with thrombosis (OR 3.5, 95% CI 2.3–5.4)
and with obstetric complications (OR 2.4, 95% CI 1.4–4.3). On the
other hand, no significant positive correlation was found for IgG anti-
β2GPI with obstetric complications (OR 1.5, 95% CI 0.6–3.7), nor for
IgG reactive against other domains of β2GPI with thrombosis (OR 0.4,
95% CI 0.3–0.6) [16].
In a separate study, 25% of 183 children with systemic lupus er-
ythematosus (SLE) were found to be anti-DI positive, whereas all pe-
diatric controls were negative [46]. A multivariate analysis showed that
both the presence of anti-DI antibodies and LAC are independently
associated with reduced annexin A5 anticoagulant activity [46]. Due to
the relatively low rate for histories of thrombosis (3.8%) in the popu-
lation, the study was not sufficiently powered to determine the asso-
ciation of anti-DI antibodies with thrombosis.
2.2. In-house developed direct anti-DI ELISA
In addition to the baculovirus system for recombinant DI, a bacterial
expression system to produce human DI [47] was used to develop a
simple direct ELISA that does not require the usage of hydrophobic
versus hydrophilic plates. In a population consisting of 22 APS patients,
20 SLE patients and 10 healthy controls, significantly higher binding
was observed for polyclonal purified IgG from APS patients compared
to that from the other groups [35]. Interestingly, the creation of mul-
tiple mutants of DI using the same bacterial system identified that aside
from G40-R43 also R39, the domain I-II interlinker, and possibly D8
and D9 play a major role in the binding to antibodies [35].
This assay has been used for detection of IgG anti-DI in two studies
[48,49]. In a population of 40 seropositive APS and 40 seronegative
APS patients (i.e. individuals with typical clinical features highly sug-
gestive for APS, but persistently negative for laboratory criteria), the
prevalence of anti-DI positivity was 27.5% in seropositive APS and
7.5% in seronegative APS [48]. Additionally in a population of 111 APS
patients, 119 SLE patients and 200 healthy controls, a lower sensitivity
of the IgG anti-DI compared to IgG anti-β2GPI measured by an in-houseTa
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ELISA for APS (40.5% versus 64.8%) was demonstrated [49]. Single
positivity for IgG anti-DI (hazard ratio (HR) 6.6, 95% CI 3.8–11.4) was
strongly associated with APS, but to a lesser extent than single IgG anti-
β2GPI (HR 33.4, 95% CI 13.0–86.1). However, in the same study, of
136 patients positive for IgG anti-CL or anti-β2GPI, 52 were also IgG
anti-DI positive, and the presence of IgG anti-DI positivity raised the HR
for APS approximately 3-fold [(HR 36.9, 95% CI 17.7–76.9) versus (HR
11.5, 95% CI 6.3–21.0)]. In addition, positivity for IgG anti-DI in-
creased the strength of association between anti-CL/anti-β2GPI posi-
tivity measured by an in-house ELISA and thrombotic manifestations in
the group of 111 patients with APS, suggesting anti-DI positivity can be
used for thrombotic risk stratification. None of the tested profiles was
significantly associated with pregnancy morbidity [49].
2.3. In-house developed competitive inhibition ELISA
A competitive inhibition ELISA assay was developed in which a
chemically synthesized DI [50] was used to inhibit binding of anti-
bodies in APS patients plasma to whole β2GP1 immobilized on a 96
wells plate [51]. In this assay, at first the DI concentration able to in-
hibit 50% of patient IgG binding to β2GPI (IC50) was calculated.
Consecutively, this concentration of DI was used to calculate the per-
centage inhibition obtained in different patient categories. The level of
inhibition proved to be higher in samples from triple positive APS pa-
tients (positive for LAC, IgG anti-CL and IgG anti-β2GPI) compared to
double (positive for IgG anti-CL and IgG anti-β2GPI) or single positive
(positive only for IgG anti-β2GPI) APS patients and healthy controls
[51]. Since triple positive APS patients are at high risk of developing
future thromboembolic events [52], this result supports the idea that
IgG anti-DI antibodies play an important pathogenic role [51]. Inter-
estingly, in preliminary experiments, anti-DI antibodies were not de-
tected by direct coating of DI onto ELISA plates. More specifically, when
plasma from APS patients and healthy controls was tested for IgG
binding to the same chemically synthesized DI coated on either a hy-
drophobic or a hydrophilic plate, the IgG anti-DI levels did not differ
between APS patients and healthy controls [51].
2.4. Commercially developed anti-DI ELISA
The first commercially developed assay to measure anti-DI anti-
bodies was from INOVA Diagnostics. Recombinant DI of β2GP1 was
expressed and purified from the baculovirus expression system [34].
This assay has been used for detection of IgG anti-DI in three patient
studies [24,40,53].
Using this ELISA, IgG anti-DI antibodies were found to be the most
prevalent antibodies (75%) in 64 patients with APS [24]. A low pre-
valence of IgG anti-DI was reported in 57 healthy children born to
mothers with various systemic autoimmune diseases (AID) and 33
children with atopic dermatitis (16% and 27%, respectively). On the
other hand, IgG antibodies recognizing DIV/V of β2GPI were pre-
ferentially detected in children (37% and 33%, respectively), whereas
isolated IgG anti-DIV/V was rare (5%) in APS and not associated with
thrombosis. This study speculated that antibodies targeting DI are pa-
thogenic, whereas those reactive with DIV/V are probably ‘innocent’
[24]. In another study including 159 anti-β2GPI positive patients
(measured by an in-house ELISA) [40], 70% of the 87 patients with
primary APS (PAPS) were positive for anti-DI reactivity. 30 asympto-
matic aPLs-carriers displayed significantly lower levels of anti-DI IgG
and higher levels of anti-DIV/V compared to the PAPS group and the
rheumatic disease (RD) group. Interestingly, no association was found
between IgG anti-DI and APS classification, thrombosis and obstetric
complications in a multivariate logistic regression model, although
compared to patients with a single event, those with recurrent throm-
bosis displayed significantly higher titers of IgG anti-DI [40]. Likewise,
IgG anti-DIV/V positivity was not associated with APS clinical mani-
festations thrombosis and pregnancy morbidity [40,54]. However,
positive anti-DI reactivity was associated with triple positivity, sug-
gesting it may be used as a risk stratification tool in APS patients. Ad-
ditionally, the ratio of anti-DI to anti-DIV/V antibodies in this study
emerged as an informative tool to identify those subjects carrying
“nonpathogenic” or “less-pathogenic” anti-β2GPI antibodies [40]. An-
other study including 326 SLE patients showed that IgG anti-β2GPI
(measured by Quanta Lite ELISA,INOVA) but not IgG anti-DI reactivity
was significantly associated with thrombosis (OR 3.3, 95% CI 1.2–8.9;
OR 1.1, 95% CI 0.4–2.9, respectively) [53].
2.5. CIA for anti-DI
Using the same recombinant DI of β2GP1 from the baculovirus ex-
pression system [34] coupled to paramagnetic beads, more recently a
CIA assay [55] has been developed for the measurement of anti-DI
antibodies. After incubation of the paramagnetic beads with serum
samples, isoluminol-labeled anti-human IgG antibodies are incubated
with the aPLs previously captured by the paramagnetic particles. Fi-
nally, an agent is added to induce chemiluminescence. Currently, two
systems are available that measure anti-DI antibodies using this tech-
nology, including the BIO-FLASH CIA from INOVA Diagnostics, Werfen,
Austria and the HemosIL Acustar CIA from Instrumentation Laboratory,
Bedford, MA, USA. The BIO-FLASH CIA and the HemosIL Acustar CIA
are identical assays using the same analytic method and reagent kits.
Since 2014, this commercially available CIA anti-DI assay has been
evaluated in 17 published studies [15,17,54,56–69].
For the classification of APS, the CIA IgG anti-DI assay has a higher
specificity (from 82.1% to 100.0%) and a lower sensitivity (from 35.9%
to 62.5%) compared to IgG anti-β2GPI test (from 71.7% to 99.1% and
from 46.2% to 82.3% for specificity and sensitivity, respectively)
among seven studies (summarized in Table 2). For the association with
clinical manifestations of APS, the ORs of IgG anti-DI assays varied in
eleven studies, ranging from 3.3 to 31.5 for thrombosis and from 1.5 to
14.6 for obstetric symptoms, probably originating from different pa-
tient and control cohorts and different cut-off values (summarized in
Table 3). Few studies failed to demonstrate a significant association of
anti-DI reactivity with thrombosis [63,68]. In one study on thrombotic
APS patients, 54% of the patients displayed anti-β2GPI antibodies,
versus only 25% for anti-DI [63]. IgG anti-DI proved not to be asso-
ciated with the site of the first event of thrombosis (OR 0.6, 95% CI
0.2–1.9), thrombosis recurrence (OR 1.0, 95% CI 0.4–2.7) nor preg-
nancy morbidity (OR 1.5, 95% CI 0.3–7.3) [63]. Another study in 178
SLE patients indicated that both the IgG anti-DI titer and IgG anti-B2GPI
titer were not associated with venous events (n=22), arterial events
(n=20), composite venous events or arterial events (n=37), respec-
tively (P= .90, 0.76 and 0.89 for IgG anti-DI titer and P= .86, 0.84
and 0.86 for IgG anti-B2GPI titer, respectively) [68]. Looking at a total
population of 426 APS and control patients or at a subpopulation of 74
IgM/IgG anti-β2GPI positive patients, IgG anti-DI positivity was sig-
nificantly associated with thrombosis (OR 14.4, 95% CI 6.0–34.8 and
OR 31.5, 95% CI 5.4–182.1, respectively) [60]. However, in a subgroup
of 60 anti-β2GPI IgG positive patients from the same study no sig-
nificant association of IgG anti-DI positivity with thrombosis was ob-
served (OR 10.3, 95% CI 0.6–166.7) [60]. On the other hand, three out
of five studies indicated IgG anti-DI was associated with pregnancy
morbidity [54,59,62]. In a cross-sectional study with 65 positive anti-
β2GPI IgG patients, pregnancy loss was present in 16 out of 39 women
(41%) positive for anti-DI reactivity and in three out of 19 women
(16%) with negative values. The association of IgG anti-DI with ob-
stetrical APS nearly reached statistical significance (P= .07) [59]. In a
case-control study including 195 control women, 199 non-severe pre-
eclampsia patients and 143 severe pre-eclampsia patients, anti-DI IgG
reactivity was associated with severe pre-eclampsia patients in the
univariate analysis. However, in the final multivariate analysis, positive
anti-β2GP1 IgG but not positive IgG anti-DI was identified as a risk
factor for severe pre-eclampsia [62]. A recently published study
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including 135 well-characterized female patients with persistent
medium-high titer of anti-β2GPI antibodies and at least one pregnancy
showed that reactivity against DI is a predictor for pregnancy morbidity
(OR 2.4, 95% CI 1.2–5.0) [54]. More specifically, IgG anti-DI sig-
nificantly predicted late pregnancy morbidity (OR 7.3, 95% CI
2.1–25.5) [54]. In addition to the clinical symptoms of APS included in
the criteria, one study in 32 APS patients indicated that the non-criteria
manifestations livedo reticularis (n=8) and heart value disease (n=9)
were associated with higher levels of IgG anti-DI (p= .005 and P= .01,
respectively) [56].
Furthermore, several studies assessed whether testing for anti-DI
adds value to current criteria laboratory tests (summarized in Table 3).
Upon comparison of IgG anti-DI assays and IgG anti-β2GPI assays, in
four of seven studies the ORs of IgG anti-DI exceeded those of IgG anti-
β2GPI for clinical manifestations (three for thrombosis, one for
thrombosis and pregnancy morbidity) [15,17,57,61]. In the remaining
three studies, despite significant correlation of IgG anti-DI with the
clinical manifestations of APS, ORs of IgG anti-DI positivity proved to
be lower than IgG anti-β2GPI positivity [60,62,65]. In severe pre-
eclampsia patients, a significant association was shown for IgG anti-
β2GPI but not IgG anti-DI in the final multivariate analysis [62]. Of
note, one study also investigated the clinical significance of testing for
IgG targeting other domains of β2GPI: neither thrombosis nor preg-
nancy morbidity was significantly correlated with IgG targeting other
domains of β2GPI [17].
Different score systems have been formulated to quantify the risk of
thrombosis/obstetric events in APS, including triple positivity (i.e. po-
sitive for LAC, IgG or IgM aCL, IgG or IgM anti-β2GPI) [70] and anti-
phospholipid score (aPL-S) [71]. Eleven studies showed that triple po-
sitive patients tend to have a significantly higher prevalence and higher
levels of IgG anti-DI than those with double-positive or single-positive
profile (summarized in Table 4). In 180 patients with hypercoagul-
ability, the thrombotic risk of the newly defined triple positive group
(positive for LAC, IgG anti-CL, IgG anti-DI) was more than twice than
that of the triple positive group (positive for LAC, IgG anti-CL, IgG anti-
β2GPI) [15]. Similarly, in 138 SLE patients, the test results of IgG anti-
DI raised the accuracy of predicting thrombosis compared to the test
results of anti-CL/ anti-β2GPI-ELISA, resulting in an increased area
under the receiver operating characteristic (ROC) curve (AUC) (0.84
versus 0.80, respectively) [67]. However, in a retrospective study in-
cluding 202 AID patients adding positivity for anti-DI to the triple po-
sitivity profile did not increase the predicting capacity for APS throm-
botic complications [65]. Similar results were obtained in a cohort
study in which no added value was demonstrated for anti-DI to the
criteria panel [60]. Also in this study, patients with a high aPL-S were
shown to display higher titers of anti-DI IgG [60]. In another study, an
adjusted aPL-S was determined, measuring reactivity against DI instead
of the whole molecule β2GPI (aPL-S-DI) [57]. When comparing the aPL-
S-DI with the traditional aPL-S reaching the same specificity of 95%, the
aPL-S-DI resulted in slightly lower OR for clinical symptoms of APS.
However, when the optimal cut-off for each aPL-S was calculated, the
aPL-S -DI resulted in the highest relative risk of having clinical
Table 4
The prevalence of IgG anti-DI positive in triple, double and single positive patients.
Publication Study IgG anti-DI positive
Year First author Design Population N Assay Cut-off Prevalence P value
2011 Banzato A [51] R Triple positive A 22 Competitive inhibition ELISA NA 25.5% S*
Double positive 15 5.0%
Single positive 9 2.0%
Control 20 0.0%
2015 Andreoli L [40] R Triple positive B 87 Direct ELISA 15.0 AU (95thp.) 80.4% S*
Double/single positive 72 48.6%
2015 Meneghel L [58] R Triple positive B NS CIA 7.1 CU (99thp.) 94.1% S*
Double positive NS 45.5%
Single positive NS 4.8%
SN-APS/HC NS 1.6%/0.6%
2015 Pengo V [59] CS Triple positive A 32 CIA 14.2 CU (99thp.) 97.0% S*
Double positive 23 43.0%
Single positive 10 10.0%
2016 De Craemer AS [60] R Triple positive B 62 CIA 20.0 CU (Manuf.) 83.9% S*
Double positive 4 50.0%
Single positive 4 0.0%
Triple negative 222 0.9%
2016 Montalvão S [63] R Triple positive B 13 CIA 20.0 CU (Manuf.) 46.0% S*
Double/single positive 28 17.0%
2016 Zhang S [17] R Triple/Double/single positive B 229 CIA 20.0 CU (Manuf.) NS S*
2017 Iwaniec T [65] R,CS Triple positive B 79 CIA 13.8 CU (99thp.) 308.2 & S*
Double positive 10 6.2 &
Single positive 14 2.0&
2017 Lee JS [15] R Triple positive A 17 CIA 40.0 CU (99thp.) 58.8% S*
Double positive 27 7.4%
Single positive 93 0.0%
Triple negative 43 0.0%
2018 Chighizola CB [54] CC Triple positive B 82 CIA 20.0 CU (NS) 195.0 ± 628.3§ S*
Double/single positive 53 4.0 ± 11.0§
2018 Marchetti T [68] Longitudinal study Triple positive B 22 CIA 14.4 AU (99 thp.) 365.4 ± 596.1§ S*
Double positive 13 137.9 ± 434.1§
Single positive 40 3.8 ± 8.7§
Abbreviations: AU: arbitrary units; CIA: chemiluminescence immunoassay; CS: cross-sectional study; CU: chemiluminescence unit; DI: domain I β2-glycoprotein I
(β2GPI); ELISA: enzyme-linked immunosorbent assay; HC: healthy control; Manuf.: manufacturer; N: number of population; NA: not applicable; NS: not specified; R:
retrospective study; SN-APS: seronegative APS; 95th/99thp.: 95th/99th percentile; S*: significantly higher prevalence or levels of IgG anti-DI positive were found in
patients with triple positivity, compared with patients with double and single aPL positivity; &: median value of IgG anti-DI; §: mean ± standard deviation (SD)
value of IgG anti-DI; A: IgG triple positive= positive lupus anticoagulant (LAC), IgG anti-CL, IgG anti-β2GPI; B: Triple positive= positive LAC, IgG or IgM anti-CL,
and IgG or IgM anti-β2GPI.
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manifestations of APS [57]. In a separate study, testing IgG anti-DI and
IgG/M anti-phosphatidylserine/prothrombin (PS/PT) showed a high
positive predictive value for the diagnosis of APS and a strong corre-
lation with the aPL-S was obtained [66]. Similarly, the thrombotic risk
associated with the combination of IgG anti-PS/PT and IgG anti-DI was
elevated 4.5 times compared to double positivity for IgG anti-PS/PT
and IgG anti-β2GPI [15].
3. Combined results on the clinical value of anti-DI antibodies
3.1. Inconsistency on clinical value of anti-DI antibodies
Most studies have shown that anti-DI positivity significantly corre-
lates with clinical manifestations of APS (Tables 2, 3 and 4). In terms of
clinical performance, compared with the anti-β2GPI assays the anti-DI
assays in general seem to be less sensitive, but (slightly) more specific
for the diagnosis of APS (Table 2). As the anti-DI assays detect a pa-
thogenic subpopulation of antibodies, the ORs for manifestations of APS
were expected to be higher than the ORs of full length anti-β2GPI as-
says. However, results were inconsistent and dependent on the assays
used to detect both anti-β2GPI and anti-DI reactivity (Table 3). None-
theless, significantly higher titers and prevalence of anti-DI antibodies
were found in high risk patients with triple positivity compared with
double and single positive patients (Table 4). Moreover, adding of IgG
anti-DI or IgG anti-DI instead of IgG anti-β2GPI in combined positive
profile markedly raised the correlation with the risk of thrombosis in
APS in several studies [15,49,66,67]. Furthermore, as with triple po-
sitivity, positive and negative values of IgG anti-DI in initial test were
consistently confirmed after 12 weeks, illustrating that IgG anti-DI po-
sitivity is a robust and reproducible marker [59,72].
For different assays detecting IgG anti-DI, the two-step anti-DI
ELISA in particular showed that the ORs of IgG anti-DI are markedly
higher than the OR of IgG antibodies targeting the whole length β2GPI
or other domains of the protein [16,38]. Moreover, this assay empha-
sized the exposure of epitope G40-R43 domain I is important for anti-
body binding. CIA is currently the most widely used method to detect
IgG anti-DI antibodies. IgG anti-DI measured by CIA seem to represent a
strong indicator for clinical manifestations of APS. However, the results
of the added clinical value of IgG anti-DI are not consistent. Some
studies showed that anti-DI display no added clinical value to the
classical aPLs panel [60,62,65]. None of the remaining three assays, the
direct anti-DI ELISA, the competitive inhibition ELISA and the com-
mercial developed INOVA anti-DI ELISA showed an added value of IgG
anti-DI compared to IgG anti-β2GPI. Taken together, the observed in-
consistency probably explains why anti-DI antibodies have not yet been
included in the laboratory criteria [19].
3.2. Towards an explanation for the observed discrepancies
The studies included in this review differ in study design, study
population and the methodology to measure the anti-DI antibodies.
These factors, together with the absence of standardization or calibra-
tion, make it very difficult to compare results of clinical studies and
accurately assess the clinical value of measuring anti-DI. Even using the
same assay for detection of anti-DI has led to discrepant results in de-
termination of the added value of anti-DI antibodies. Differences in
methods of calculating cut-off values, statistical analysis method, la-
boratory-specific handlings or protocols and different study populations
may affect the interpretation of the results and lead to the observed
discrepancies. Two studies independently showed the effect of different
cut-off values: increasing cut-off values resulted in significantly higher
ORs [61,73]. One study including patients with APS, AID, disease
controls and healthy controls showed different results for correlation of
IgG anti-DI positivity with thrombosis in the total population of 426
patients versus in 60 IgG anti-β2GPI positive patients [60].
A similar situation is observed for the anti-β2GPI assays, in which
external quality assessment program reports show a wide variability in
results over different centers [74–77]. Previous research has shown the
importance of a certain antigen density to enable divalent binding of
antibodies [78,79], as well as a hydrophilic solid phase surface to coat
β2GPI thereby inducing a conformational change resulting in the ex-
posure of a cryptic pathogenic epitope in DI. Antibodies directed to this
cryptic epitope G40-R43 are a major pathological subset of antibodies
[27–29,35–38,41]. Hence, results obtained by anti-β2GPI assays de-
pend on the density and the conformation of the coated β2GPI (i.e. the
exposure of the epitope G40-R43), which are affected by the type of
solid phase surface used to immobilize β2GPI and source of protein. As
in anti-DI assays DI is coated instead of the full protein, similar pro-
blems were not expected. However, taken into account the positive
charge of epitope G40-R43, the charge of the coating surface possibly
influences the availability of the G40-R43 epitope. A neutral coating
surface is hypothesized to result in an arbitrary orientation of the DI,
resulting in exposure of epitope G40-R43. On the other hand, a negative
surface binds the positive epitope preventing its availability for anti-
bodies. Based on this hypothesis and the evidence provided with the
two-step ELISA, we assume that the differences in the type of solid
phase surface used to immobilize DI and hence the exposure of the
pathogenic DI epitope in the available anti-DI assays that add up to the
variation in results. Looking at the other anti-DI assays, a possible
charge of the beads cannot be excluded, rendering the exposure of
epitope G40-R43 on DI uncertain. Exactly the same question can be
made for the other available assays, as except for the two- step anti-DI
ELISA, the charge of the solid phase surfaces used to immobilize DI are
unknown. This may provide an explanation why both studies using the
commercially developed anti-DI ELISA from INOVA Diagnostics to
measure anti-DI showed that there is no significant association with
thrombosis [40,53]. A clinical study using an in-house developed direct
anti-DI ELISA showed significantly but less clinical value of anti-DI
compared to anti-β2GPI [49]. Similarly, although with a competitive
inhibition anti-DI ELISA a significant difference was found in patients
with triple positivity compared with patients with double or single
positivity and healthy controls, a direct anti-DI ELISA with the same DI
did not find differences in IgG anti-DI between APS patients and con-
trols, independent of using hydrophobic or hydrophilic plates, different
coating/washing/blocking buffers and concentrations of DI [51]. In
addition, although CIA can provide a greater surface for antibodies
binding to DI, three studies showed significantly but less clinical value
of IgG anti-DI compared to IgG anti-β2GPI [60,62,65]. This problem
seems to be avoided in the in-house developed two-step ELISA, where
the ratio between the OD measured with a hydrophobic plate versus
hydrophilic plate is used to determine positivity.
We aimed to verify our hypothesis by determining the exposure of
the pathogenic G40-R43 epitope in the commercially available aDI CIA
method. Therefore, normal pooled plasma was spiked with two human-
derived monoclonal antibodies P1-117 and P2-6. Antibody P1-117,
recognizing epitope G40-R43 only available when β2GPI is in its open
conformation, and P2-6, recognizing domain I independently of its
conformation [80]. Our unpublished results show that P2-6 can be
detected while no signal is obtained for P1-117 (data not shown).
Contrary to the expectation, this anti-DI assay thereby does not expose
the epitope G40-R43 on the surface of the beads, therefore patient
samples with antibodies recognizing the epitope G40-R43 will be
missed. Our results are consistent with previous results obtained with
the CIA anti-β2GPI assay (HemosIL Acustar) in which P1-117 showed
lower reactivity compared to P2–6, demonstrating a reduced G40-R43
availability [81]. In addition, a high agreement (69%~92%) was ob-
served between anti-β2GPI and anti-DI in the same CIA device
[17,59,60,65], suggesting that both assays measure almost the same
antibody population directed against domain I but not to the G40-R43
epitope. On the other hand, two studies detecting IgG anti-DI using the
two-step ELISA found that approximately half (58% and 57%, respec-
tively) of IgG anti-β2GPI bound DI [16,38]. Taken together, these
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results suggest that the two-step ELISA measures a more specific anti-DI
antibody population directed against G40-R43, compared to the com-
mercially available anti-DI CIA assay detecting all antibodies to domain
I, as well as to other domains. As a result, the two-step ELISA did show
an added clinical value of the anti-DI positivity compared to the full-
length anti-β2GPI, demonstrated by the higher OR for thrombosis and
pregnancy morbidity [16,38]. Our data highlight the importance of not
only measuring G40-R43 exposure in the full length anti-β2GPI assays,
but also in the anti-DI assays to be certain that at least this pathogenic
antibody population is not missed.
Apart from the coating principle, also the density of the coated DI
and the source of DI may influence the results. Regarding the density,
especially the CIA with paramagnetic beads provide a three-dimen-
sional platform and larger surface for antibodies binding to DI [82].
Three different sources of DI are used in the available assays: DI ob-
tained through a baculovirus expression system, an Escherichia coli ex-
pression system or by a chemical synthesis. So far, the effect of pro-
duction on the conformation of DI and hence the availability of the
pathogenic G40-R43 epitope is not known.
4. Conclusion
In summary, given all the in vitro and in vivo evidence, anti-DI
assays were expected to be very powerful in the classification of APS
patients. The majority of clinical studies did find a significant associa-
tion of anti-DI antibodies with clinical symptoms of APS and a higher
specificity was demonstrated compared with anti-β2GPI antibodies. As
specifically antibodies to DI are detected, a more uniform result was
expected, resulting in an improved risk stratification and tailored
treatment for APS patients. However, multiple anti-DI assays are
available and suffer from the same problems as the full-length anti-
β2GPI assays. To assess the added value of anti-DI assays, several im-
portant issues urgently need to be addressed. As for anti-β2GPI assays,
standardization of anti-DI assays is of utmost importance. This stan-
dardization in our view also includes the confirmation of a satisfactory
exposure of the epitope G40-R43 to ascertain that at least one specific
pathogenic antibody population is measured. Additionally, so far only
retrospective studies were performed to determine the added value of
DI antibodies. Prospective, well designed multicenter studies are ur-
gently required to clarify the clinical utility of the anti-DI assays.
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